Our Markets

The African Pharmaceutical markets is broken up into five main components, of which Veld focuses on four of them, which are Western Africa, Central Africa, Eastern Africa and Southern Africa.

Western Africa is comprised of 16 Nations, Niger, Nigeria, Mali, Burkina Faso, Benin, Togo, Ghana, CoteD’Ivoire, Liberia, Sierra Leone, Guinea, Guinea Bissau, Gambia, Senegal, Mauritania and Cape Verde.

Central Africa is comprised of 9 Nations, Chad, Cameroon, Central African Republic, Democratic Republic of Congo, Republic of the Congo, Equatorial Guinea, Gabon, Sao Tome & Principe, Angola.

Eastern Africa is comprised of 18 Nations, Eritrea, Djibouti, South Sudan, Ethiopia, Somalia, Kenya, Uganda, Rwanda, Burundi, Tanzania, Malawi, Zambia, Zimbabwe, Mozambique , Madagascar, Seychelles, Comoros, Mauritius.

Southern Africa is comprised of 5 Nations, including South Africa, Namibia, Botswana, Swaziland, and Lesotho.

These African regions, include some of the lowest GDP/Capital nations in the world as well as some hydrocarbon rich markets that yield levels of GDP/Capita in the range of some Mediterranean and Central Eastern European nations. The Pharmaceutical market in Africa was forecasted by IQVIA to eclipse $25 Bn in 2022. In removing some of the Northern African markets, this gives a total market opportunity of some $15 B making this region about twice the size of the Saudi Arabian market with 31 x the population. Nevertheless, given the heterogeneity of the markets there are always opportunities in the African continent from markets with robust reimbursement systems to markets where NGOs play a significant role in the delivery of pharmaceuticals.

Orphan products and Rare Disease medicines are in their early infancy on the African sub-continent but with the advancement of healthcare and the growth in the macroeconomic situation there are patient in need who require and can receive the innovative therapies that are currently available.